{"id":16169,"date":"2020-10-05T21:42:43","date_gmt":"2020-10-05T19:42:43","guid":{"rendered":"https:\/\/www.ifpma.org\/?post_type=publications&#038;p=16169"},"modified":"2024-06-19T11:08:58","modified_gmt":"2024-06-19T09:08:58","slug":"ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector","status":"publish","type":"publications","link":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/","title":{"rendered":"Ethical third party intermediary relationships in the biopharmaceutical sector"},"content":{"rendered":"<p class=\"intro\">To ensure and improve ongoing access for patients and HCPs to innovative, reliable, and effective medicines and vaccines, it is often necessary for research and development-based biopharmaceutical manufacturers (\u201cCompanies\u201d) to contract with third parties to support their business activities.<\/p>\n<p>These third parties can operate as clinical research organizations, distributors, wholesalers, distribution or sales agents, consultants, brokers, commission agents, and\/or independent sales representatives (\u201cThird Party Intermediaries\u201d or \u201cTPIs\u201d). They serve an integral role in the biopharmaceutical sector and health systems, helping ensure patients, HCPs, institutions, and associations have access to company products and services.\u00a0This Note for Guidance intends to provide non-binding best practices for Companies when working with TPIs.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>To ensure and improve ongoing access for patients and HCPs to innovative, reliable, and effective medicines and vaccines, it is often necessary for research and development-based biopharmaceutical manufacturers (\u201cCompanies\u201d) to contract with third parties to support their business activities. These third parties can operate as clinical research organizations, distributors, wholesalers, distribution or sales agents, consultants,&#8230;<\/p>\n","protected":false},"featured_media":16170,"template":"","publication_type":[7],"topic":[29],"class_list":["post-16169","publications","type-publications","status-publish","has-post-thumbnail","hentry","publication_type-position-paper","topic-ethics"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ethical third party intermediary relationships in the biopharmaceutical sector | IFPMA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ethical third party intermediary relationships in the biopharmaceutical sector | IFPMA\" \/>\n<meta property=\"og:description\" content=\"To ensure and improve ongoing access for patients and HCPs to innovative, reliable, and effective medicines and vaccines, it is often necessary for research and development-based biopharmaceutical manufacturers (\u201cCompanies\u201d) to contract with third parties to support their business activities. These third parties can operate as clinical research organizations, distributors, wholesalers, distribution or sales agents, consultants,...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/\" \/>\n<meta property=\"og:site_name\" content=\"IFPMA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IFPMA\/\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-19T09:08:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/06\/Ethical-third-party-intermediaries_NfG.png\" \/>\n\t<meta property=\"og:image:width\" content=\"634\" \/>\n\t<meta property=\"og:image:height\" content=\"896\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@IFPMA\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/\",\"url\":\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/\",\"name\":\"Ethical third party intermediary relationships in the biopharmaceutical sector | IFPMA\",\"isPartOf\":{\"@id\":\"https:\/\/www.ifpma.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/06\/Ethical-third-party-intermediaries_NfG.png\",\"datePublished\":\"2020-10-05T19:42:43+00:00\",\"dateModified\":\"2024-06-19T09:08:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#primaryimage\",\"url\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/06\/Ethical-third-party-intermediaries_NfG.png\",\"contentUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/06\/Ethical-third-party-intermediaries_NfG.png\",\"width\":634,\"height\":896},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ifpma.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/www.ifpma.org\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ethical third party intermediary relationships in the biopharmaceutical sector\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ifpma.org\/#website\",\"url\":\"https:\/\/www.ifpma.org\/\",\"name\":\"IFPMA\",\"description\":\"Innovating to improve health worldwide\",\"publisher\":{\"@id\":\"https:\/\/www.ifpma.org\/#organization\"},\"alternateName\":\"International Federation of Pharmaceutical Manufacturers and Associations\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ifpma.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ifpma.org\/#organization\",\"name\":\"IFPMA\",\"alternateName\":\"International Federation of Pharmaceutical Manufacturers and Associations\",\"url\":\"https:\/\/www.ifpma.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png\",\"contentUrl\":\"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png\",\"width\":1379,\"height\":733,\"caption\":\"IFPMA\"},\"image\":{\"@id\":\"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/IFPMA\/\",\"https:\/\/x.com\/IFPMA\",\"https:\/\/www.linkedin.com\/company\/ifpma\/\",\"https:\/\/www.youtube.com\/user\/ifpma\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ethical third party intermediary relationships in the biopharmaceutical sector | IFPMA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/","og_locale":"en_US","og_type":"article","og_title":"Ethical third party intermediary relationships in the biopharmaceutical sector | IFPMA","og_description":"To ensure and improve ongoing access for patients and HCPs to innovative, reliable, and effective medicines and vaccines, it is often necessary for research and development-based biopharmaceutical manufacturers (\u201cCompanies\u201d) to contract with third parties to support their business activities. These third parties can operate as clinical research organizations, distributors, wholesalers, distribution or sales agents, consultants,...","og_url":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/","og_site_name":"IFPMA","article_publisher":"https:\/\/www.facebook.com\/IFPMA\/","article_modified_time":"2024-06-19T09:08:58+00:00","og_image":[{"width":634,"height":896,"url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/06\/Ethical-third-party-intermediaries_NfG.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@IFPMA","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/","url":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/","name":"Ethical third party intermediary relationships in the biopharmaceutical sector | IFPMA","isPartOf":{"@id":"https:\/\/www.ifpma.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#primaryimage"},"image":{"@id":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/06\/Ethical-third-party-intermediaries_NfG.png","datePublished":"2020-10-05T19:42:43+00:00","dateModified":"2024-06-19T09:08:58+00:00","breadcrumb":{"@id":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#primaryimage","url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/06\/Ethical-third-party-intermediaries_NfG.png","contentUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2024\/06\/Ethical-third-party-intermediaries_NfG.png","width":634,"height":896},{"@type":"BreadcrumbList","@id":"https:\/\/www.ifpma.org\/publications\/ethical-third-party-intermediary-relationships-in-the-biopharmaceutical-sector\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ifpma.org\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/www.ifpma.org\/publications\/"},{"@type":"ListItem","position":3,"name":"Ethical third party intermediary relationships in the biopharmaceutical sector"}]},{"@type":"WebSite","@id":"https:\/\/www.ifpma.org\/#website","url":"https:\/\/www.ifpma.org\/","name":"IFPMA","description":"Innovating to improve health worldwide","publisher":{"@id":"https:\/\/www.ifpma.org\/#organization"},"alternateName":"International Federation of Pharmaceutical Manufacturers and Associations","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ifpma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ifpma.org\/#organization","name":"IFPMA","alternateName":"International Federation of Pharmaceutical Manufacturers and Associations","url":"https:\/\/www.ifpma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png","contentUrl":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-landscape-narrow.png","width":1379,"height":733,"caption":"IFPMA"},"image":{"@id":"https:\/\/www.ifpma.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IFPMA\/","https:\/\/x.com\/IFPMA","https:\/\/www.linkedin.com\/company\/ifpma\/","https:\/\/www.youtube.com\/user\/ifpma"]}]}},"_links":{"self":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publications\/16169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publications"}],"about":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/types\/publications"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/media\/16170"}],"wp:attachment":[{"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/media?parent=16169"}],"wp:term":[{"taxonomy":"publication_type","embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/publication_type?post=16169"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ifpma.org\/wp-json\/wp\/v2\/topic?post=16169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}